Cefazolin MIP: Uses, Dosage & Side Effects

What Is Cefazolin MIP and What Is It Used For?

Quick Answer: Cefazolin MIP is a first-generation cephalosporin antibiotic given by injection or infusion. It is primarily used for preventing surgical infections (surgical prophylaxis) and treating a range of bacterial infections including skin, bone, urinary tract, and bloodstream infections.

Cefazolin belongs to the beta-lactam family of antibiotics, specifically the first-generation cephalosporins. It was first introduced in the 1970s and has since become one of the most frequently used parenteral antibiotics in clinical practice worldwide. The drug is manufactured by MIP Pharma and is available as a powder for reconstitution into a solution for injection or intravenous infusion.

The primary mechanism of action involves inhibition of bacterial cell wall synthesis. Cefazolin binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane, disrupting the cross-linking of peptidoglycan chains that form the structural backbone of the bacterial cell wall. This results in osmotic instability and ultimately bacterial cell lysis and death. Because human cells do not have cell walls, cefazolin selectively targets bacteria while causing minimal damage to the host.

Cefazolin demonstrates excellent activity against most gram-positive cocci, particularly methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pyogenes (Group A streptococcus), and Streptococcus pneumoniae. It also has activity against certain gram-negative bacteria including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. However, it lacks activity against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species, and most anaerobic organisms.

Approved Clinical Indications

Cefazolin MIP is approved for the treatment and prevention of infections caused by susceptible microorganisms in the following conditions:

• Surgical prophylaxis: Prevention of postoperative infections in cardiac, orthopedic, abdominal, gynecological, and other surgical procedures. This is by far the most common indication worldwide.
• Skin and soft tissue infections: Including cellulitis, wound infections, and abscesses caused by susceptible staphylococci and streptococci.
• Bone and joint infections: Osteomyelitis and septic arthritis caused by susceptible organisms, often as part of a longer treatment course.
• Urinary tract infections: Including complicated UTIs and pyelonephritis caused by susceptible gram-negative organisms.
• Endocarditis: Infective endocarditis caused by susceptible staphylococci, particularly in native valve infections.
• Septicemia: Bloodstream infections (bacteremia) caused by susceptible pathogens.
• Respiratory tract infections: Including pneumonia caused by susceptible organisms, though other antibiotics are often preferred for this indication.

What Should You Know Before Taking Cefazolin MIP?

Quick Answer: Before receiving cefazolin, inform your healthcare provider about any allergies to antibiotics (especially penicillins or cephalosporins), kidney disease, gastrointestinal problems, or if you are pregnant or breastfeeding. Cefazolin is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics.

Contraindications

Cefazolin MIP must not be administered in the following situations:

• Known hypersensitivity to cefazolin, any other cephalosporin antibiotic, or any of the excipients contained in the product. Allergic reactions can range from mild skin rashes to life-threatening anaphylaxis.
• History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to any beta-lactam antibiotic (penicillins, carbapenems). While cross-reactivity between penicillins and cephalosporins is relatively low (approximately 1-2%), the consequences of anaphylaxis are severe enough to warrant extreme caution.

Warnings and Precautions

Several important warnings and precautions should be considered before and during cefazolin therapy:

• Penicillin allergy: Patients with a history of non-severe penicillin allergy (e.g., mild rash) may still receive cefazolin, but should be monitored closely. The overall cross-reactivity rate between penicillins and first-generation cephalosporins is estimated at 1-2%. Patients with a history of anaphylaxis to penicillin should generally avoid cephalosporins unless no suitable alternative exists.
• Clostridioides difficile-associated diarrhea (CDAD): As with nearly all antibiotics, cefazolin may alter normal intestinal flora and promote overgrowth of Clostridioides difficile, leading to potentially severe colitis. If significant diarrhea develops during or after cefazolin treatment, CDAD should be considered and appropriate testing initiated.
• Renal impairment: Cefazolin is primarily eliminated by the kidneys. In patients with impaired renal function, accumulation may occur, leading to increased serum levels and a higher risk of adverse effects including neurotoxicity and seizures. Dose adjustment based on creatinine clearance is mandatory.
• Superinfection: Prolonged use of cefazolin may result in the overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate measures should be taken.
• Interference with laboratory tests: Cefazolin may produce a false-positive reaction for glucose in urine when using copper sulfate-based tests (e.g., Benedict's reagent, Clinitest). Glucose oxidase-based methods (e.g., Clinistix) are not affected. Cefazolin may also cause a false-positive direct Coombs test.
• Sodium content: Cefazolin is administered as the sodium salt. Each gram of cefazolin contains approximately 2.1 mmol (48 mg) of sodium. This should be considered in patients on sodium-restricted diets or those with conditions such as heart failure or renal impairment.

Pregnancy and Breastfeeding

Cefazolin crosses the placenta and is found in fetal tissues and amniotic fluid. However, extensive clinical experience and observational data have not revealed evidence of teratogenicity or adverse fetal effects. Cefazolin is classified as a Pregnancy Category B drug (FDA classification), meaning that animal reproduction studies have not demonstrated a fetal risk and there are no adequate, well-controlled studies in pregnant women, or animal studies have shown an adverse effect but adequate studies in pregnant women have failed to demonstrate a risk.

In practice, cefazolin is one of the most commonly used antibiotics during pregnancy, particularly for surgical prophylaxis during cesarean section. The American College of Obstetricians and Gynecologists (ACOG) recommends cefazolin as the preferred agent for cesarean delivery prophylaxis.

Cefazolin is excreted in low concentrations in human breast milk. While the amounts are generally considered too small to affect the nursing infant, the theoretical risk of sensitization, disruption of the infant's intestinal flora, and potential fungal overgrowth (candidiasis) should be considered. Most guidelines consider cefazolin compatible with breastfeeding, but the nursing infant should be monitored for signs of diarrhea, candidiasis, or allergic reaction.

How Does Cefazolin MIP Interact with Other Drugs?

Quick Answer: Cefazolin can interact with several medications including probenecid (which increases cefazolin levels), anticoagulants like warfarin (increased bleeding risk), aminoglycosides (increased risk of kidney damage), and loop diuretics (increased nephrotoxicity risk). Always inform your healthcare provider of all medications you are taking.

Drug interactions with cefazolin are clinically important and can affect both the efficacy and safety of treatment. Healthcare providers must carefully evaluate a patient's complete medication list before initiating cefazolin therapy. The following table summarizes the most significant known interactions:

Major Interactions

Minor Interactions

The following interactions are of lower clinical significance but should still be noted:

• Oral contraceptives: While cefazolin may theoretically reduce the efficacy of combined oral contraceptive pills by altering gut flora involved in enterohepatic recirculation of estrogen, clinical evidence for this interaction is weak. Nevertheless, some guidelines recommend additional contraceptive precautions during antibiotic therapy.
• Live vaccines: Cefazolin, like other antibiotics, may reduce the efficacy of live bacterial vaccines (e.g., BCG, live typhoid vaccine) by killing the vaccine organisms. Live vaccines should ideally be administered at least 24 hours after the last dose of cefazolin.
• Metformin: Both cefazolin and metformin are renally eliminated. Concomitant use in patients with borderline renal function may theoretically increase the risk of metformin accumulation, although this interaction is rarely clinically significant.

What Is the Correct Dosage of Cefazolin MIP?

Quick Answer: The standard adult dose of cefazolin is 1-2 g every 6-8 hours for active infections, or 1-2 g as a single dose 30-60 minutes before surgery for prophylaxis. Dosing depends on the type and severity of infection, patient weight, and renal function. Dose adjustment is required in kidney impairment.

Cefazolin MIP is available as a 2 g vial of powder that must be reconstituted before administration. It can be given by intravenous (IV) injection over 3-5 minutes, by IV infusion over 30-60 minutes, or by deep intramuscular (IM) injection. The specific dose, route, and duration depend on the clinical indication, severity of infection, patient weight, and renal function.

Adults

Children

In pediatric patients (aged 1 month and older), cefazolin dosing is calculated based on body weight. The recommended dose is 25-50 mg/kg/day divided into 3-4 doses (every 6-8 hours). For severe infections, the dose may be increased to 100 mg/kg/day. The maximum daily dose in children should not exceed the adult dose. Neonates (under 1 month) require specialized dosing based on gestational age and weight, typically 25 mg/kg every 8-12 hours. Pediatric dosing should always be determined by a physician experienced in neonatal or pediatric medicine.

Elderly

Elderly patients often have age-related decline in renal function that may not be reflected by serum creatinine alone. Dose adjustment based on estimated creatinine clearance (CrCl) is recommended. In elderly patients with normal renal function, no dose adjustment is necessary. However, close monitoring of renal function is advisable, particularly in patients receiving prolonged courses or concomitant nephrotoxic agents.

Renal Impairment Dosing

Missed Dose

Since cefazolin is administered by healthcare professionals in a hospital setting, missed doses are uncommon. If a dose is inadvertently missed, it should be administered as soon as possible. If it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not administer a double dose to compensate for a missed one. The healthcare team will ensure that dosing remains on schedule throughout the treatment course.

Overdose

Overdosage with cefazolin, particularly in patients with renal impairment, may lead to symptoms including pain, inflammation, and phlebitis at the injection site, dizziness, paresthesias (numbness and tingling), and headache. In severe cases or in patients with significantly impaired renal function, high serum levels may precipitate seizures, encephalopathy, and neuromuscular excitability. Treatment of overdose is primarily supportive. Hemodialysis can partially remove cefazolin from the circulation, though its effectiveness is limited due to the drug's protein binding characteristics.

What Are the Side Effects of Cefazolin MIP?

Quick Answer: Common side effects include injection site reactions (pain, swelling), diarrhea, nausea, and vomiting. Less common but more serious effects include allergic reactions, Clostridioides difficile-associated diarrhea, blood abnormalities, and rarely, seizures. Most side effects are mild and resolve after completing treatment.

Like all medicines, cefazolin can cause side effects, although not everyone experiences them. The side effects are classified below by frequency according to the standard convention used in medical literature and by the European Medicines Agency (EMA). Understanding the frequency helps patients and healthcare professionals make informed decisions about treatment. Most side effects of cefazolin are mild and transient, resolving spontaneously once treatment is completed.

If you experience severe or persistent diarrhea during or after cefazolin treatment, particularly if it contains blood or mucus, contact your healthcare provider immediately as this may indicate Clostridioides difficile-associated colitis, which requires prompt diagnosis and treatment. Do not take antidiarrheal medications without medical advice in this situation, as they may worsen the condition.

Allergic reactions to cefazolin can range from mild skin rashes to severe anaphylaxis. Signs of anaphylaxis include difficulty breathing, swelling of the face, lips, tongue or throat, rapid heartbeat, severe skin rash or hives, and a drop in blood pressure. Anaphylaxis is a medical emergency requiring immediate treatment with epinephrine and supportive care.

How Should You Store Cefazolin MIP?

Quick Answer: Store unopened vials at room temperature (below 25°C / 77°F) in the original packaging, protected from light. Once reconstituted, use immediately or refrigerate and use within 24 hours. Do not freeze reconstituted solutions.

Proper storage of cefazolin MIP is essential to maintain the drug's potency and ensure patient safety. The powder for injection/infusion in its unopened vial is relatively stable at controlled room temperature, but once reconstituted, the solution has a limited shelf life that depends on the diluent used, concentration, and storage conditions.

Unopened Vials

• Temperature: Store at or below 25°C (77°F). Do not freeze.
• Light protection: Keep in the original outer carton to protect from light.
• Shelf life: Refer to the expiration date printed on the vial and outer packaging. Do not use after the expiry date.
• Visual inspection: Before reconstitution, check that the powder is white to off-white. Do not use if the powder appears discolored or contains visible particles.

Reconstituted Solutions

• For IV injection: Reconstitute with sterile water for injection. Use within 24 hours if stored in a refrigerator (2-8°C) or within 6 hours at room temperature.
• For IV infusion: After initial reconstitution, further dilute in 50-100 mL of compatible IV fluid (0.9% sodium chloride or 5% dextrose). Use within 24 hours if refrigerated.
• For IM injection: Reconstitute with sterile water for injection or 0.5% lidocaine solution (to reduce injection pain). Use immediately after reconstitution.
• Visual check: Reconstituted solutions should be clear to slightly yellow. Do not use if the solution is cloudy, contains particulate matter, or is deeply discolored.

Keep all medicines out of the sight and reach of children. Do not dispose of unused or expired medication via household waste or wastewater. Ask your pharmacist about appropriate disposal methods to help protect the environment. Hospital pharmacies and nursing staff are responsible for ensuring proper storage conditions and checking expiration dates before administration.

What Does Cefazolin MIP Contain?

Quick Answer: Each vial of Cefazolin MIP contains 2 g of cefazolin (as cefazolin sodium). The sodium salt form allows the powder to be dissolved in water for injection. Each gram contains approximately 2.1 mmol (48 mg) of sodium.

Active Ingredient

The active substance is cefazolin, present as cefazolin sodium. Each vial contains cefazolin sodium equivalent to 2 g of cefazolin. Cefazolin sodium is a white to off-white crystalline powder that is freely soluble in water. The molecular formula of cefazolin sodium is C₁₄H₁₃N₈NaO₄S₃ with a molecular weight of approximately 476.5 g/mol.

Excipients

Cefazolin MIP powder for injection contains no additional excipients. The powder consists solely of cefazolin sodium. This is typical for parenteral cephalosporin formulations, as the sodium salt form provides sufficient solubility and stability without the need for additional inactive ingredients.

Sodium Content

Each gram of cefazolin contains approximately 2.1 mmol (48 mg) of sodium. For the 2 g vial, this means approximately 4.2 mmol (96 mg) of sodium per dose. This is an important consideration for patients on sodium-restricted diets or those with conditions that require careful sodium management, such as congestive heart failure, hepatic cirrhosis with ascites, or severe renal impairment. Healthcare providers should factor the sodium content into the patient's total daily sodium intake calculations.